7月1日晚，复旦大学经济学院举办"稳定币与国际金融大变局"线上研讨会。 会上，复旦大学数字金融研究中心主任周光友指出，稳定币的兴起不仅代表了一种新型货币形式的崛 起，更是对现有货币体系的一次重大挑战。应推动人民币锚定型稳定币的发行，例如在上海自贸区或大 湾区等尝试发行稳定币。 同时，推进人民币国际化也需要考虑制度性战略重构。 最新数据显示，2024年稳定币的交易总额已高达27.6万亿美元，首度超越Visa与MasterCard等传统支付 巨头的合计交易额。从原本小众的DeFi（去中心化金融）应用，到跨境汇款、电商支付，甚至大型零售 场景，稳定币已逐步渗透到全球金融基础设施，尤其在跨境交易、资金清算与费用控制方面展现出压倒 性优势。 周光友指出，这些数据凸显了稳定币在支付领域的强大竞争力，其基于区块链的技术特性使得交易更加 便捷、高效，基本能够满足全球用户的支付需求，逐渐改变了传统支付格局，而且稳定币的影响可能会 越来越大。 此外，2025年6月主流稳定币合计达到2625亿美元，虽然仅相当于美元存款的1%，但相较于2020年，它 的市值增长了40倍。据渣打银行预测，稳定币规模三年内将达2万亿美元。从稳定币的增长 ...

中经院表示，制造业的保守观望、股市回调所带来的负面财富效应、消费者信心低迷等，均影响经济走 势。连贤明分析，厂商目前虽未陷入悲观，但乐观情绪仍显不足，美国关税政策对制造业的影响有望于 6、7月间逐渐明朗。(完) 中经院介绍，5月PMI五项组成指标中，经季节调整后，新增订单与人力雇用仍处于紧缩，生产活动由 紧缩转为扩张，供货商交货时间延长，存货则持续增加。制造业六大产业中，电子暨光学、电力暨机械 设备、化学暨生技医疗三大产业呈现扩张，交通工具、基础原物料、食品暨纺织产业则仍呈现紧缩。 非制造业方面，中经院指出，5月未经季节调整的台湾非制造业采购经理人指数(NMI)已连续3个月扩 张，本月NMI微升0.9个百分点至51.9%。非制造业商业活动与新增订单指数同步转为扩张，但未来展望 指数连续第三个月呈现紧缩。 中新社台北6月2日电 (记者张晓曦)台湾中华经济研究院(简称"中经院")2日在台北公布，经季节调整后， 今年5月台湾制造业采购经理人指数(PMI)回升2.1个百分点至51%，与4月相比由紧缩转为扩张。中经院 院长连贤明指出，厂商决策仍偏保守，目前"谈不上乐观"。 PMI高于50%表示景气处于扩张期，低于50% ...

enGene Holdings (ENGN) 2025 Conference May 05, 2025 02:00 PM ET Speaker0 For our next presentation, it's from NGIN, and we have the pleasure of having Ron Cooper, the CEO, here to present for us. So take it away, Ron. Thank you. Speaker1 Well, good afternoon, everybody. It's a real pleasure to be here. You know, first of all, thanks to the conference organizers. It's great to be back in back in Canada. NGEN is a company form formed in Canada. Our headquarters is in Montreal. Our labs are there, and we have ...

- Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCHAUMBURG, Ill. and IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-st ...

在全球金融格局加速变革的当下，离岸金融作为金融皇冠上的明珠已成为国际金融中心建设和人民币国 际化的关键力量；我国开展离岸金融活动，为上海和香港这两个国际金融中心带来了全新的发展机遇。 香港作为历经"惊涛骇浪"的国际金融中心，已具备强大的竞争力与抗风险能力。上海与香港并非竞争对 立关系，而是相互依存、协同共进的命运共同体，上海更是香港国际金融中心的坚强后盾与重要补充。 上海开展离岸金融对香港国际金融中心地位的影响 一是潜在影响。随着上海等地积极推进离岸金融业务，出台优惠政策、优化市场准入条件，可能会分流 部分原本集中于香港的离岸金融业务。内地加大税收优惠力度，降低企业运营成本，会吸引部分金融机 构和企业将业务重心转向内地，进而减少香港金融市场的业务量。 上海离岸金融业务的快速发展创造了大量就业机会和广阔的职业发展空间。若上海在薪酬待遇、职业晋 升机会和生活成本等综合因素上更具优势，可能导致部分香港金融人才流入上海。 上海离岸金融市场的崛起加剧了市场竞争，对香港金融市场的传统优势构成挑战。上海金融机构加快金 融产品创新，推出一系列离岸金融新产品和服务，与香港市场形成竞争态势。在离岸人民币方面，上海 人民币计价的金 ...

Summary of Protara Therapeutics (TARA) Update / Briefing April 28, 2025 Company Overview - **Company**: Protara Therapeutics - **Focus**: Development of TARA-two, an investigational treatment for non-muscle invasive bladder cancer (NMIBC) Key Industry Insights - **Clinical Trial**: Ongoing Phase II ADVANCE-two clinical trial of TARA-two in NMIBC patients - **Treatment Landscape**: TARA-two is positioned as a competitive option in the evolving NMIBC treatment landscape, particularly for BCG unresponsive patients Core Findings and Arguments 1. **Positive Interim Results**: TARA-two demonstrated a complete response (CR) rate of 100% at any time and 100% at six months in the BCG unresponsive cohort, with rates of 80% at nine months and 67% at twelve months [12][15] 2. **Durable Responses**: The treatment shows durable responses at twelve months in both BCG unresponsive and naive cohorts, with 76% CR at any time in the naive cohort [15] 3. **Safety Profile**: TARA-two exhibited a favorable safety profile, with most adverse events being grade one and transient, and no patients discontinued due to adverse events [16] 4. **Mechanism of Action**: TARA-two activates a broader immunologic profile compared to other therapies, potentially leading to durable antitumor responses [9][14] 5. **Regulatory Engagement**: The company is in discussions with the FDA regarding the design of registrational studies for both BCG unresponsive and naive patient populations [15][81] Additional Important Insights 1. **Patient Enrollment**: The company has seen an increase in trial enrollment due to site expansion efforts, with 17 patients currently enrolled [12][28] 2. **Future Milestones**: Protara anticipates additional data updates and milestones throughout the year, including a preplanned analysis of 25 BCG unresponsive patients by the end of 2025 [19][29] 3. **Combination Therapy Potential**: The company is exploring systemic priming and combination therapies to enhance treatment efficacy and patient quality of life [45][47] 4. **Market Positioning**: TARA-two is viewed as a potential best-in-class treatment for NMIBC, with characteristics that drive adoption among healthcare providers [32][33] Conclusion - Protara Therapeutics is making significant strides in the development of TARA-two for NMIBC, with promising interim results and a strong safety profile. The company is well-positioned to capitalize on upcoming milestones and regulatory discussions, potentially transforming the treatment landscape for patients with NMIBC.

90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechn ...

enGene Holdings (ENGN) FY 2025 Conference February 11, 2025 08:40 AM ET Company Participants Alex Nichols - Chief Strategy & Operations OfficerRyan Daws - CFO Conference Call Participants Leland Gershell - Managing Director - Senior Biotechnology Analyst Leland Gershell Great. Good morning, everyone, or good afternoon, depending where you may be. Welcome back to another session here at, Oppenheimer's thirty fifth annual, Healthcare Life Sciences annual conference. I'm Leland Grischell, one of the biotech an ...